These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 18398462

  • 1. Glial progenitor-like phenotype in low-grade glioma and enhanced CD133-expression and neuronal lineage differentiation potential in high-grade glioma.
    Rebetz J, Tian D, Persson A, Widegren B, Salford LG, Englund E, Gisselsson D, Fan X.
    PLoS One; 2008 Apr 09; 3(4):e1936. PubMed ID: 18398462
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Glioma cell populations grouped by different cell type markers drive brain tumor growth.
    Prestegarden L, Svendsen A, Wang J, Sleire L, Skaftnesmo KO, Bjerkvig R, Yan T, Askland L, Persson A, Sakariassen PØ, Enger PØ.
    Cancer Res; 2010 Jun 01; 70(11):4274-9. PubMed ID: 20460538
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Isolation and partial characterization of a new human glioblastoma cell line.
    Brehar FM, Bleotu C, Stefan LM, Buzgariu W, Chivu M, Utoiu E, Matei L, Ciurea AV, Tascu A.
    Chirurgia (Bucur); 2009 Jun 01; 104(4):453-61. PubMed ID: 19886054
    [Abstract] [Full Text] [Related]

  • 9. Clinicopathological and Prognostic Significance of CD133 in Glioma Patients: A Meta-Analysis.
    Han M, Guo L, Zhang Y, Huang B, Chen A, Chen W, Liu X, Sun S, Wang K, Liu A, Li X.
    Mol Neurobiol; 2016 Jan 01; 53(1):720-727. PubMed ID: 25589004
    [Abstract] [Full Text] [Related]

  • 10. TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth.
    Di K, Linskey ME, Bota DA.
    Oncogene; 2013 Oct 17; 32(42):5038-47. PubMed ID: 23178488
    [Abstract] [Full Text] [Related]

  • 11. Stem cell marker CD133 affects clinical outcome in glioma patients.
    Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende CC.
    Clin Cancer Res; 2008 Jan 01; 14(1):123-9. PubMed ID: 18172261
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Clinical value of CD133 and nestin in patients with glioma: a population-based study.
    Dahlrot RH, Hansen S, Jensen SS, Schrøder HD, Hjelmborg J, Kristensen BW.
    Int J Clin Exp Pathol; 2014 Jan 01; 7(7):3739-51. PubMed ID: 25120750
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. What is the clinical value of cancer stem cell markers in gliomas?
    Dahlrot RH, Hermansen SK, Hansen S, Kristensen BW.
    Int J Clin Exp Pathol; 2013 Jan 01; 6(3):334-48. PubMed ID: 23412423
    [Abstract] [Full Text] [Related]

  • 19. Study on the proliferation and drug-resistance of human brain tumor stem-like cells.
    Qin K, Jiang X, Zou Y, Wang J, Qin L, Zeng Y.
    Cell Mol Neurobiol; 2010 Aug 01; 30(6):955-60. PubMed ID: 20526804
    [Abstract] [Full Text] [Related]

  • 20. CD90 is identified as a candidate marker for cancer stem cells in primary high-grade gliomas using tissue microarrays.
    He J, Liu Y, Zhu T, Zhu J, Dimeco F, Vescovi AL, Heth JA, Muraszko KM, Fan X, Lubman DM.
    Mol Cell Proteomics; 2012 Jun 01; 11(6):M111.010744. PubMed ID: 22203689
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.